News

To improve the quality of work and cooperation with its customers, in April of this year, the Latvian Medicines Verification Organisation (LZVO) conducted a survey with Software Suppliers (SWS) about the LZVO's customer service. An invitation to participate in the survey was sent to all SWS’ who cooperate with the LZVO and offer technical solutions for Latvian end users – pharmacies, hospitals, healthcare institutions and pharmaceutical wholesalers.

European Medicines Verification Organisation (EMVO) would like to highlight once again the consequences following Product Withdrawal and Batch recall and remind you that these are irreversible actions.

Latvijas Zāļu verifikācijas organizācija (LZVO) atjaunojusi un papildinājusi informāciju sadaļā “Jautājumi un atbildes”.

On May 12, at the European Medicines Verification Organisation’s (EMVO) General Assembly meeting, the NMVO Observers within EMVO’s Board for 2023 from the National Medicines Verification Organizations (NMVOs) were approved. As one of the observers representing the group of small-scale countries, will be the Latvian Medicines Verification Organisation (LZVO) and its Chairwoman of the Board Inese Erdmane.

Latvian Medicines Verification System’s (LZVS) developer Arvato has prepared the next Core release 2.0, which will replace the current version 1.11. With the new version of the Core release, several functional changes and improvements will be introduced, including Brexit changes – activation of additional response codes, as well as strengthening of system security.

The Latvian Medicines Verification Organisation (LZVO) in the fifth issue of the Newsletter (April 2023) looks back at the celebration of the fourth anniversary of the medicine verification system and looks at the current affairs of the first quarter of 2023.